4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol

This MedLibrary.org supplementary page on 4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol
Systematic (IUPAC) name
trans-4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol
Identifiers
CAS number  ?
ATC code  ?
PubChem 9887338
Chemical data
Formula C22H28BrNO 
Mol. mass 402.367 g/mol
SMILES eMolecules & PubChem
Physical data
Melt. point 208–210 °C (406–410 °F)
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Legal

Routes  ?

4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol (BDPC) is a potent μ-opioid agonist with a distinctive chemical structure which is not closely related to other established families of opioid drugs.1 It was invented by the chemists Daniel Lednicer and Philip VonVoigtlander in 1979.23

This compound was found to be around 10,000x more potent than morphine in animal studies (although newer data suggest it is much less potent than this, perhaps only ~600x morphine)4, however due to its structural differences from other opioid drugs it would be difficult to represent as being "substantially similar in chemical structure" to any controlled drugs, although it does retain the high-affinity opioid pharmacophore.5 Its structural distinctiveness from controlled opioid drugs makes it likely that BDPC would be legal throughout the world.

BDPC has never been used in humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and respiratory depression which could be harmful or fatal. Tolerance and dependence would be expected to develop rapidly based on the potency of the drug, as it is of a similar strength to carfentanil and so would most likely cause pronounced tachyphylaxis following repeated dosing, as is seen with the potent fentanyl analogues.



See also

References

  1. ^ Lednicer D, VonVoigtlander PF, Emmert DE. 4-amino-4-arylcyclohexanones and their derivatives: a novel class of analgesics. 2. Modification of the carbonyl function. Journal of Medicinal Chemistry. 1981 Apr;24(4):404-8. PMID 7265128
  2. ^ Lednicer D, VonVoigtlander PF. 4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol, an extremely potent representative of a new analgesic series. Journal of Medicinal Chemistry 1979; 22(10):1157-1158. PMID 513062
  3. ^ Daniel Lednicer. 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use. US Patent 4366172
  4. ^ Liu ZH, Jin WQ, Dai QY, Chen XJ, Zhang HP, Chi ZQ. Opioid activity of C8813, a novel and potent opioid analgesic. Life Sciences. 2003 May 30;73(2):233-41. PMID 12738037
  5. ^ Martin J, Andrews P. Conformation-activity relationships of opiate analgesics. Journal of Computer-Aided Molecular Design. 1987 Apr;1(1):53-72.

Wikipedia content modification information:

  • This page was last modified on 4 November 2008, at 21:22.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.